CSPC Pharmaceutical Group Limited (01093) said "Epirubicin Hydrochloride Liposome Injection" developed by its subsidiary CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. was granted approval by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China.
The product is able to reduce the distribution of drug in normal tissues by encapsulating the active ingredient epirubicin hydrochloride in PEGylated liposome and achieve targeting to tumour area with the enhanced permeability and retention (EPR) effect.
全新etnet健康網購，送你【健骨維他命D3(1000IU)】乙樽(價值$108)► 立即行動！
